chrisvoncsefalvay/vaers-outcomes huggingface dataset:
rash, on chest, arms, wrists; heard something in the bottom of lungs; felt like I was getting pneumonia; sore throat; congestion in my nose; lost my voice; dry cough; slept all day long; chills; felt very ill; bones hurt; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (felt very ill), BONE PAIN (bones hurt), SOMNOLENCE (slept all day long), OROPHARYNGEAL PAIN (sore throat) and NASAL CONGESTION (congestion in my nose) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.  Concomitant products included PAIN RELIEF BACK PAIN for Back pain.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Apr-2021, the patient experienced MALAISE (felt very ill), BONE PAIN (bones hurt) and CHILLS (chills). On 25-Apr-2021, the patient experienced SOMNOLENCE (slept all day long). On 27-Apr-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat), NASAL CONGESTION (congestion in my nose), APHONIA (lost my voice), COUGH (dry cough) and FEELING ABNORMAL (felt like I was getting pneumonia). On 05-May-2021, the patient experienced FEELING ABNORMAL (heard something in the bottom of lungs). On an unknown date, the patient experienced RASH (rash, on chest, arms, wrists). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, MALAISE (felt very ill), BONE PAIN (bones hurt), SOMNOLENCE (slept all day long), OROPHARYNGEAL PAIN (sore throat), NASAL CONGESTION (congestion in my nose), APHONIA (lost my voice), COUGH (dry cough), FEELING ABNORMAL (heard something in the bottom of lungs), FEELING ABNORMAL (felt like I was getting pneumonia) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment medication included Zpack  Concomitant products included 24 other daily medications (names unknown at call) for an unknown indication.
This spontaneous report as received from a certified medical assistant refers to a 2 year old male patient. The patient had no pertinent medical history. On 12-APR-2013 the patient was vaccinated with PNEUMOVAX 23, .5 ml, intramuscular. Lot number, expiry date and dose number were not reported. Concomitant therapies included AUGMENTIN for an unknown indication which was given two weeks prior to the date of vaccination. On 13-APR-2013, reported as 24 hours after onset of therapy the patient experienced cellulitis (hospitalization) and inflammation of the muscles (hospitalization). The dates of hospitalization were not reported. Unspecified cultures and scans were taken at the hospital, the results were not reported. The patient present status was reported as recovering, the event(s) from which the patient was recovering was not specified. Additional information has been requested.
Could not get the 2nd dose due to an emergency; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 21-Apr-2021 and was forwarded to the company on 21-Apr-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Could not get the 2nd dose due to an emergency) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Could not get the 2nd dose due to an emergency). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Could not get the 2nd dose due to an emergency) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
MOTHER REPORTS PT C/O "STOMACH HURTING AND DIARRHEA YESTERDAY EVENING.  HAD HIVES ALL OVER WHEN HE WOKE UP."  PATIENT DID SEE NP AT THE CLINIC.  PER MOM SAID THE "REACTION WAS DUE TO THE MEASLE VACCINE AND WAS TOLD TO GIVE PATIENT BENADRYL FOR THE HIVES."
dizziness; headache; nausea; fatigue; This spontaneous case was reported by a nurse and describes the occurrence of DIZZINESS (dizziness), HEADACHE (headache), NAUSEA (nausea) and FATIGUE (fatigue) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Apr-2021 at 3:52 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced DIZZINESS (dizziness), HEADACHE (headache), NAUSEA (nausea) and FATIGUE (fatigue). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) on 02-Apr-2021 at a dose of 25 milligram. At the time of the report, DIZZINESS (dizziness), HEADACHE (headache), NAUSEA (nausea) and FATIGUE (fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Apr-2021, Blood pressure measurement: 136/69 mmHg (abnormal) 136/69. On 02-Apr-2021, Heart rate: 70 (normal) 70 per minute. On 02-Apr-2021, Oxygen saturation: 97 (normal) 97 percent.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   After experiencing the events, the  patient laid down on a cot and was monitored by one of the registered nurses. The patient sat up for 10-15 minutes and felt better.  No relevant concomitant medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 21-May-2021: Follow up received on 21 May 2021 included no new information.
Patient developed symptoms of cough, fatigue, muscle aches, headache, sore throat, and nasal congestion on 7/27/2021.  Tested positive for COVID on 7/30/2021
Urinary tract infection; stomach spasms; Back pain; Stomach cramps; vomiting; food poisoning; Acute diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of URINARY TRACT INFECTION (Urinary tract infection), DIARRHOEA (Acute diarrhea), ABDOMINAL RIGIDITY (stomach spasms), BACK PAIN (Back pain) and FOOD POISONING (food poisoning) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced DIARRHOEA (Acute diarrhea) and FOOD POISONING (food poisoning). On 10-Apr-2021, the patient experienced ABDOMINAL RIGIDITY (stomach spasms), BACK PAIN (Back pain), ABDOMINAL PAIN UPPER (Stomach cramps) and VOMITING (vomiting). On an unknown date, the patient experienced URINARY TRACT INFECTION (Urinary tract infection). At the time of the report, URINARY TRACT INFECTION (Urinary tract infection) outcome was unknown and DIARRHOEA (Acute diarrhea), ABDOMINAL RIGIDITY (stomach spasms), BACK PAIN (Back pain), FOOD POISONING (food poisoning), ABDOMINAL PAIN UPPER (Stomach cramps) and VOMITING (vomiting) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported.  No treatment information provided.  Action taken with mRNA-1273 in response to the event was unknown
Fever 101, sore throat, muscle aches, running nose, neck ache, slight stomach upset. 24 hours follow up vaccination. Still symptoms present at 83 hours.
no appetite; Chills; bad headache; Body aches; Nausea, no appetite; Tired and fatigued; Injection site became painful; Injection site became swollen; Injection site developed a 5 cm red patch; Injection site felt like it was having an allergic reaction; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (bad headache), PAIN (Body aches), NAUSEA (Nausea, no appetite), DECREASED APPETITE (no appetite) and FATIGUE (Tired and fatigued) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event. Concomitant products included Congestive Heart Failure Medications and Atrial Fibrillation Medications.    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Apr-2021, the patient experienced HEADACHE (bad headache), PAIN (Body aches), NAUSEA (Nausea, no appetite), FATIGUE (Tired and fatigued), VACCINATION SITE PAIN (Injection site became painful), VACCINATION SITE SWELLING (Injection site became swollen), VACCINATION SITE ERYTHEMA (Injection site developed a 5 cm red patch) and VACCINATION SITE REACTION (Injection site felt like it was having an allergic reaction). On 10-Apr-2021, the patient experienced CHILLS (Chills). On an unknown date, the patient experienced DECREASED APPETITE (no appetite). At the time of the report, HEADACHE (bad headache), PAIN (Body aches), NAUSEA (Nausea, no appetite), FATIGUE (Tired and fatigued), VACCINATION SITE PAIN (Injection site became painful), VACCINATION SITE SWELLING (Injection site became swollen), VACCINATION SITE ERYTHEMA (Injection site developed a 5 cm red patch), VACCINATION SITE REACTION (Injection site felt like it was having an allergic reaction) and CHILLS (Chills) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
mild sore arm; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (mild sore arm) in an elderly male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030L20A, 006M20A, 046C21A and 066K21A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (mild sore arm). At the time of the report, VACCINATION SITE PAIN (mild sore arm) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant and treatment medication was not reported.  The patient had mild sore arm.   This case was linked to MOD-2023-746996, MOD-2023-747013.
18OCT96 seen in ER for 3cm induration of lt deltoid;site of inj of flu shot on 16OCT96;
systemic symptoms of fever, lethargy, poor feeding, vomiting diarrhea and erythematous fine papular dermatoses of about 48 hour duration..  The MOP describes no noted immediate reaction, such as urticaria, flushing, SOB, wheeze, cough, emesis extreme irritability.  She reports  about 2-3 hours later he developed a fine papular rash to his limbs, stomach, neck and back. The lesions would last several hours and new ones would develop. About an hour after the dermatoses, she noted development of fever  which peaked at 101, which she treated with tylenol. He was very sleepy and stopped feeding. About two-three hours after (6-8 hours after vaccine receipt) that he developed emesis and diarrhea. All symptoms continued for about 2 days and resolved.
Dizziness, blacking out, fainted and was unconscious for several minutes, Profuse sweating, chills, nausea, arm pain, headache, fever.
Tested positive for COVID-19; This spontaneous case was reported by a pharmacist (subsequently medically confirmed) and describes the occurrence of SARS-COV-2 TEST POSITIVE (Tested positive for COVID-19) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 05-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Feb-2021, the patient experienced SARS-COV-2 TEST POSITIVE (Tested positive for COVID-19). At the time of the report, SARS-COV-2 TEST POSITIVE (Tested positive for COVID-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Feb-2021, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patients treatment information included azithromycin (Z-pack) and Steroid. No concomitants provided
Almost fainted; A spontaneous report was received from a Consumer  concerning a 73-year-old, male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced almost fainted.  The patient's medical history, was not provided by the reporter. Concomitant use of the Products was not Provided by the reporter.  On 16-Mar-2021 at 10:10 am, approximately eight hours prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 intramuscularly in the left arm for prophylaxis of COVID-19 infection.  On 16-Mar-2021, after first dose of vaccine.  At 6:00 pm, the patient almost fainted while having shower and was referred to HCP.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the event, almost fainted  was unknown.  The Causality between the event and the m-RNA-1273 Vaccine was not provided.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Hurts when moving arm far (like reaching behind back). Went to doctor. Doctor told him to use OTC acetaminophen and warm compress. Patient says is slightly better, almost did not go to doctor this morning.
onset approx 24hr of recv vax;pt devel erythema & induration @ immun site;area expanded to site 5.5 x 4.0cm (approx) sore & itchy;no systemic sx;
No additional AE reported; patient received a dose of VAQTA on 4/26/2021 that had a labeled expiry of 4/15/2021; This spontaneous report was received from a certified medical assistant and refers to a 32-year-old patient. There was no information about patient's pertinent medical history, drug reactions, allergies and concomitant medications. On 26-APR-2021, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) at a dose of 1 ml, lot # T014590, lot # 15-APR-2021, both confirmed to be valid for for prophylaxis (strength, dose #, route of administration and anatomical location were not reported). No additional adverse events reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T014590; expirationdate: 15-APR-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
No reaction to first shot on January21.  After 2nd shot on February 23, had one day of  soreness in arm, feeling achy and ill. Then on March14 face started going numb on left side, eye drooping.  Went to ER and after tests, diagnosed Bell?s Palsey. Was given Valacyclovir Hcl and Prednisone 20 mg. for  5 days.  Still experiencing these symptoms.
Swelling in lymph nodes; Both locations are tender and sore; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 34 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 29Oct2021 13:30 (Lot number: FF2890) at the age of 34 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "known allergies: Sulfa" (unspecified if ongoing); "known allergies: Bees" (unspecified if ongoing); "known allergies: Strawberries" (unspecified if ongoing); "known allergies: Onion" (unspecified if ongoing); "known allergies: Garlic" (unspecified if ongoing). Concomitant medication(s) included: SINGULAIR; CALCIUM; CRANBERRY; ZYRTEC [CETIRIZINE HYDROCHLORIDE]. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EN6207, Location of injection: Arm Left, Vaccine Administration Time: 06:00 PM), administration date: 16Mar2021, when the patient was 34 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 2, Batch/Lot No: EW0151, Location of injection: Arm Left, Vaccine Administration Time: 05:45 PM), administration date: 08Apr2021, when the patient was 34 years old, for COVID-19 immunization. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 2021, outcome "not recovered", described as "Swelling in lymph nodes"; LYMPH NODE PAIN (non-serious) with onset 2021, outcome "not recovered", described as "Both locations are tender and sore". Therapeutic measures were not taken as a result of lymphadenopathy, lymph node pain.  Additional information: Swelling in lymph nodes around left collarbone and in left armpit. Both locations are tender and sore. The vaccine was administered at public health clinic/veterans administration facility. No other vaccine in four weeks. No covid prior vaccination. No covid tested post vaccination.  No follow-up attempts are possible. No further information is expected.
My arm swelled to three times its size at the site of the injection and radiating about 5 inches out in each direction. The area was red and warm to touch. The swelling, redness and warmth lasted for 6 days.  On day 8, the swelling has gone down but I still have redness radiating about 1 inch in all directions from the site of injection and bruising.
Sudden tightness in muscle along front of abdomen, below rib cage.  Lasted approximately 15 minutes.
MONDAY(9 MARCH 2009): EVENING - HEADACHE, CHILLS. LATE NIGHT - HEADACHE, MILD FEVER., TUESDAY (10 MARCH 2009): HEADACHE, SLIGHT NAUSEA, FATIGUE., WEDNESDAY (11 MARCH 2009) HEADACHE ALL DAY
ELECTRIC SHOCK SENSATIONS; STOMACH PAIN; HEADACHE, NAUSEA, MUSCLE SORENESS; LACK OF ENERGY AND TIREDNESS; This spontaneous report received from a patient concerned a 52 year old female. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient was non alcoholic, non smoker and had no known drug allergies. the patient did not have any drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported) dose was not reported, administered on 29-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 01-MAY-2021, the subject experienced lack of energy and tiredness. On 02-MAY-2021, the subject experienced electric shock sensations, stomach pain, headache, nausea, muscle soreness. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from stomach pain on 02-MAY-2021, and headache, nausea, muscle soreness, and had not recovered from electric shock sensations, and lack of energy and tiredness. This report was non-serious.
Employee had shortness of breath, diarrhea, vomiting, fatigue and hypoxia and was taken by ambulance on 7/17/21 where he was given IV fluids and sent home. He returned to Emergency Room on 7/22/21 due to excessive thirst, frequent urination, blurred vision, and nausea. Employee was hyperglycemic with a blood sugar of 600. IV fluids given.
Patient was administered a 3 years and older Influenza vaccine when a 6-35 months Influenza was indicated for usage.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-May-2021 at 12:07 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 24-May-2021, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 36.  Concomitant products were not provided.  On 24-May-2021, Excursion time was 9 AM, temperature was 35, total doses given for the day was unknown, On 24-May-2021, Excursion time was 8 AM, temperature was 35, total doses given for the day was unknown and on 24-May-2021, Excursion time was 9 AM, temperature was 35, total doses given for the day was unknown. Condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 18-May-2021, vial was moved to clinic on 24-May-2021. 3 vials were sent to clinic. Vaccine BUD date was 17-Jun-2021.   The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.   Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
diagnosed with COVID on 8/11/21; went to hospital on 8/16/21 with SOB, weakness, fever, confusion; hx of chronic kidney disease, type 2 diabetes
As I was driving home from vaccine I first noticed blurry vision, then extreme dizziness.  My hands were trembling and heart started racing. A sensation like I was going to pass out came over my body. I never did pass out.  All symptoms subsided within 20 minutes except the dizziness.... that persisted for about 1.5 hours . EXTREME dizziness. Tingly lips 8 hours later.